Cases from the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients with Genitourinary Cancers — A Special Audio Supplement


Current and future integration of immune checkpoint inhibitors into the management of urothelial bladder cancer (UBC)

Track 1: Case (Dr Cole): A 76-year-old woman with metastatic UBC experiences a complete response to a checkpoint inhibitor
Track 2: Side-effect profile and efficacy of immune checkpoint inhibitors for UBC
Track 3: Selection of first-line therapy for patients with asymptomatic metastatic UBC
Track 4: Case (Dr Martins): A 68-year-old man has a minimal antitumor response to neoadjuvant chemotherapy for bladder cancer

Existing and emerging roles of anti-PD-1/PD-L1 antibodies in renal cell carcinoma (RCC)

Track 5: Case (Dr Rupard): A 59-year-old man with metastatic clear cell RCC experiences disease progression on first-line pazopanib
Track 6: Use of immune checkpoint inhibitors for metastatic RCC after disease progression on a tyrosine kinase inhibitor
Track 7: Efficacy of immune checkpoint inhibitors in patients with RCC and brain metastases
Track 8: Choice of first-line therapy for patients with asymptomatic metastatic RCC

Role of immune checkpoint inhibitors in prostate cancer

Track 9: Case (Dr Favaro): A 59-year-old man with metastatic prostate cancer that progresses through multiple lines of therapy is found to have microsatellite instability (MSI)-high disease and receives pembrolizumab
Track 10: Activity of checkpoint inhibitors in patients with CD274 (PD-L1) gene amplification
Track 11: Efficacy of immune checkpoint inhibitors in patients with MSI-high prostate cancer

Patterns of response to immune checkpoint inhibitors

Track 12: Case (Dr Glynn): An 85-year-old man receives a checkpoint inhibitor as third-line therapy for metastatic RCC
Track 13: Pseudoprogression versus true progression in patients receiving immune checkpoint inhibitors
Track 14: Duration of therapy with anti-PD-1/PD-L1 antibodies

Recognition and management of toxicities associated with immune checkpoint inhibitors

Track 15: Management of dermatologic toxicities related to anti-PD-1/PD-L1 antibodies
Track 16: Toxicity of anti-PD-1/PD-L1–anti-CTLA-4 antibody combinations
Track 17: Use of immune checkpoint inhibitors in patients with preexisting autoimmune disease
Charles G Drake, MD, PhD
Professor of Medicine
Cancer Immunotherapy Programs
Columbia University Medical Center
New York, New York
Peter H O’Donnell, MD
Assistant Professor
Department of Medicine
Section of Hematology/Oncology
Genitourinary Oncology Program
The University of Chicago
Chicago, Illinois
Elizabeth R Plimack, MD, MS
Director, Genitourinary Clinical Research
Associate Professor
Department of
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania
Thomas Powles, MBBS, MRCP, MD
Professor of Urology Oncology
Director of St Bartholomew’s Cancer Centre
Queen Mary University of London
London, United Kingdom
David I Quinn, MBBS, PhD
Medical Director
Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine
and Blood Diseases
USC Norris Comprehensive
Cancer Center
Los Angeles, California
Suzanne Cole, MD
Oklahoma City, Oklahoma
Justin P Favaro, MD, PhD
Charlotte, North Carolina
Philip T Glynn, MD
Springfield, Massachusetts
Joseph Martins, MD
Tyler, Texas
Erik J Rupard, MD
West Reading, Pennsylvania
Neil Love, MD
Research To Practice
Miami, Florida